HEME ARGINATE IN ACUTE PORPHYRIA
精氨酸血红素治疗急性卟啉症
基本信息
- 批准号:6413632
- 负责人:
- 金额:$ 27.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-12-01 至 2001-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The purpose of this project is to study heme arginate for the treatment of the acute porphyrias (acute intermittent porphyria, variegate porphyria, and hereditary coproporphyria). Heme arginate (Normosang(R), Leiras) is a stable heme preparation for intravenous use that was developed and studied in Europe for acute porphyrias, but has not been available in the United States. The heme preparation currently approved by the FDA as an orphan product for the treatment of these disorders has a number of disadvantages, including poor chemical stability, a short shelf life and troublesome side effects such as coagulation abnormalities and phlebitis at the site of intravenous infusion. These features have limited the application of heme treatment in porphyria patients in the United States. Therefore, availability of heme arginate would be a distinct advantage to patients with these disorders. The aims of these studies are 1) to examine the safety and efficacy of heme arginate in patients with acute attacks of porphyria in terms of producing remissions of symptoms and lowering porphyrin precursors; 2) to study the value of heme arginate infusions for the prevention of frequently occurring attacks of porphyria; 3) to carry out dose-ranging studies of effects of heme arginate on reducing porphyrin precursor levels in stable patients with acute intermittent porphyria. Enrollment in these multicenter studies has been completed and data is being analyzed in cooperation with the manufacturer with the aim of supporting the licensing of heme arginate in the U.S. The efficacy of a preventive regimen using heme therapy has been demonstrated for the first time.
本研究旨在探讨血红素精氨酸治疗急性卟啉症(急性间歇性卟啉症、杂色卟啉症、遗传性粪卟啉症)的疗效。 精氨酸血红素(Normosang(R),Leiras)是一种稳定的血红素制剂,用于静脉注射,在欧洲开发和研究用于急性卟啉症,但在美国尚未上市。 目前被FDA批准为用于治疗这些疾病的孤儿产品的血红素制剂具有许多缺点,包括化学稳定性差、保质期短和麻烦的副作用,例如静脉内输注部位的凝血异常和静脉炎。 这些特征限制了血红素治疗在美国卟啉病患者中的应用。因此,血红素精氨酸的可用性将是一个明显的优势,这些疾病的患者。 这些研究的目的是:1)检查血红素精氨酸盐在缓解症状和降低卟啉前体方面对卟啉病急性发作患者的安全性和有效性; 2)研究血红素精氨酸盐输注对预防频繁发生的卟啉病发作的价值; 3)开展血红素精氨酸盐降低急性间歇性卟啉病稳定期患者卟啉前体水平的剂量范围研究。这些多中心研究的入组已经完成,正在与制造商合作分析数据,目的是支持血红素精氨酸在美国的许可。首次证明了使用血红素治疗的预防方案的有效性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KARL E ANDERSON其他文献
KARL E ANDERSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KARL E ANDERSON', 18)}}的其他基金
STUDIES IN PORPHYRIA III, HEME, AND TIN MESOPORPHYRIN IN ACUTE PORPHYRIAS
急性卟啉症中卟啉症 III、血红素和中卟啉锡的研究
- 批准号:
6566687 - 财政年份:2001
- 资助金额:
$ 27.93万 - 项目类别:
STUDIES IN PORPHYRIA III, HEME, AND TIN MESOPORPHYRIN IN ACUTE PORPHYRIAS
急性卟啉症中卟啉症 III、血红素和中卟啉锡的研究
- 批准号:
6413626 - 财政年份:2000
- 资助金额:
$ 27.93万 - 项目类别:
STUDIES IN PORPHYRIA III, HEME, AND TIN MESOPORPHYRIN IN ACUTE PORPHYRIAS
急性卟啉症中卟啉症 III、血红素和中卟啉锡的研究
- 批准号:
6305243 - 财政年份:1999
- 资助金额:
$ 27.93万 - 项目类别:
相似海外基金
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 27.93万 - 项目类别:
CAPRISA CASCADE Clinical Trials Network Clinical Research Site
CAPRISA CASCADE 临床试验网络临床研究网站
- 批准号:
10754981 - 财政年份:2023
- 资助金额:
$ 27.93万 - 项目类别:
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN)
提供生物医学和行为研究资源以及临床研究协调服务以支持 NIDA 临床试验网络 (CTN)
- 批准号:
10617997 - 财政年份:2022
- 资助金额:
$ 27.93万 - 项目类别:
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN)
提供生物医学和行为研究资源以及临床研究协调服务以支持 NIDA 临床试验网络 (CTN)
- 批准号:
10538151 - 财政年份:2021
- 资助金额:
$ 27.93万 - 项目类别:
Admin. Supp. for NCI P30 Cancer Center Grants to Facilitate the Development of Standardized Electronic Treatment Plan Builds for NCI-Supported Clinical Trials Applicable Across Clinical Research Sites
行政。
- 批准号:
10442122 - 财政年份:2021
- 资助金额:
$ 27.93万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10624966 - 财政年份:2021
- 资助金额:
$ 27.93万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10515803 - 财政年份:2021
- 资助金额:
$ 27.93万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10258627 - 财政年份:2021
- 资助金额:
$ 27.93万 - 项目类别:
New Mexico Clinical Trials Node: Clinical research and practice to address substance use in diverse, rural and underserved populations
新墨西哥州临床试验节点:解决多样化、农村和服务不足人群的药物使用问题的临床研究和实践
- 批准号:
10581505 - 财政年份:2019
- 资助金额:
$ 27.93万 - 项目类别:
New Mexico Clinical Trials Node: Clinical research and practice to address substance use in diverse, rural and underserved populations
新墨西哥州临床试验节点:解决多样化、农村和服务不足人群的药物使用问题的临床研究和实践
- 批准号:
10379715 - 财政年份:2019
- 资助金额:
$ 27.93万 - 项目类别: